Finished Medicine of Amoxicillin and Clavulanate Potassium Tablet 875mg+125mg

• Customization: Available
• Application: Penicillin Antibacterial
• Usage Mode: for Oral Administration
• Model NO.: NCPC-HBV00709
• State: Solid
• Shape: Capsules
• Type: Organic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: 375mg*6 Tabeltel
• Specification: 0.5KG
• Trademark: OEM
• Origin: China
• HS Code: 3004101200
• Production Capacity: 1billion/Year

Product Description

 

Package

375mg*6 tabeltel

 

Section 19A approved medicine

Amoxicillin and clavulanate potassium tablets, USP 875mg/125mg (Aurobindo)

Section 19A approval holder

Medsurge Healthcare Pty Ltd ABN 92 124 728 892

Phone

1300 788 261

Approved until

31 January 2024

Status

Current

Medicines in short supply/unavailable

AMCLAVOX DUO FORTE 875/125, amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium) 125 mg tablets blister pack AUST R: 288119

Indication(s)

Amoxicillin and clavulanate potassium tablets, USP 875mg/125mg (Aurobindo) are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to Microbiology):

• Urinary Tract Infections (complicated and uncomplicated)
• Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis
• Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis
• Skin and Skin Structure infections

Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. However, when there is reason to believe an infection may involve any of the β-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate.

The treatment of mixed infections caused by amoxicillin susceptible organisms and β-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises such as SINOPHARM, CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.

Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.

At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the SINOPHARM authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.